The short version of bioavailability fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-20 and is reviewed periodically as new material appears.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Sickle cell disorders, which are the most prevalent form of hemoglobinopathy. Sickle hemoglobin (HbS) is prone to polymerize when deoxygenated, precipitating within the red blood cell. This damages the RBC membrane resulting in its premature destruction and consequent anemia. Unstable hemoglobin variants are mutations that cause the hemoglobin molecule to precipitate, spontaneously or upon oxidative stress, resulting in hemolytic anemia. Precipitated, denatured hemoglobin can attach to the inner layer of the plasma membrane of the red blood cell (RBC) forming Heinz bodies, leading to premature destruction of the RBC and anemia. Change in oxygen affinity. High or low oxygen affinity hemoglobin molecules are more likely than normal to adopt the relaxed (R, oxy) state or the tense (T, deoxy) state, respectively. High oxygen affinity variants (R state) cause polycythemia (e.g., Hb Chesapeake, Hb Montefiore). Low oxygen affinity variants can cause cyanosis (e.g., Hb Kansas, Hb Beth Israel).
== Further reading == Bhardwaj, S; De Meyer, Arnoud (2003). "Biocon India". INSEAD Case Study. INSEAD: 12. Reference no. 803-037-1. Retrieved 15 October 2025 – via The Case Centre. Palepu, Krishna G; Chepuri, Ananth (2008). "Biocon Limited". Harvard Business School Case Study. Harvard Business Publishing: 36. Reference no. 9-107-083. Retrieved 15 October 2025 – via The Case Centre.
Glycogenolysis is the breakdown of glycogen (n) to glucose-1-phosphate and glycogen (n-1). Glycogen branches are catabolized by the sequential removal of glucose monomers via phosphorolysis, by the enzyme glycogen phosphorylase.
Sources: en.wikipedia.org
In early 1987, he persuaded 11 Doobie alumni to join him for a concert to benefit veterans' causes. Answering the call were Tom Johnston, Pat Simmons, Jeff Baxter, John McFee, John Hartman, Michael Hossack, Chet McCracken, Michael McDonald, Cornelius Bumpus, Bobby LaKind and Tiran Porter, plus their long-time record producer and good friend, Ted Templeman. There were no surplus bass players as Weeks had other commitments. They soon discovered that tickets were in great demand, so the concert quickly evolved into a 12-city tour that began on May 21, 1987, in San Diego. The third concert, held at the Hollywood Bowl, was reportedly the venue's fastest sell-out since the Beatles had played there just over 20 years earlier. The band performed selections from every album using a wide variety of instrumentation that they could not have previously duplicated onstage without the expanded lineup. Baxter and McFee played pedal steel and violin, respectively, during "Black Water" and "Steamer Lane Breakdown". "Without You" featured four drummers and four lead guitarists. Producer Ted Templeman played percussion and LaKind sometimes played Knudsen's drum set while Knudsen went to the front of the stage to join the chorus. Templeman also played the drum set on "What a Fool Believes", as he did on the original hit record. The tour culminated (sans McDonald, LaKind, McFee and Knudsen) at the Glasnost-inspired July 4 "Peace Concert" in Moscow, with Bonnie Raitt, James Taylor and Santana sharing the bill.
intensive farming methods requires 214 liters (47 imp gal; 57 U.S. gal) of water; using hydroponics, 70 liters (15 imp gal; 18 U.S. gal); and only 20 liters (4.4 imp gal; 5.3 U.S. gal) using aeroponics. Hydroponic cultures lead to highest biomass and protein production compared to other growth substrates, of plants cultivated in the same environmental conditions and supplied with equal amounts of nutrients. Hydroponics is not only used on earth, but has also proven itself in plant production experiments in Earth orbit.
=== Cancer === While Aβ has been implicated in cancer development, prompting studies on a variety of cancers to elucidate the nature of its possible effects, results are largely inconclusive. Aβ levels have been assessed in relation to a number of cancers, including esophageal, colorectal, lung, and hepatic, in response to observed reductions in risk for developing Alzheimer's disease in survivors of these cancers. All cancers were shown to be associated positively with increased Aβ levels, particularly hepatic cancers. This direction of association however has not yet been established. Studies focusing on human breast cancer cell lines have further demonstrated that these cancerous cells display an increased level of expression of amyloid precursor protein.
=== Databases of orthologous genes and de novo orthology inference tools === Given their tremendous importance for biology and bioinformatics, orthologous genes have been organized in several specialized databases that provide tools to identify and analyze orthologous gene sequences. These resources employ approaches that can be generally classified into those that use heuristic analysis of all pairwise sequence comparisons, and those that use phylogenetic methods. Sequence comparison methods were first pioneered in the COGs database in 1997. These methods have been extended and automated in twelve different databases the most advanced being AYbRAH Analyzing Yeasts by Reconstructing Ancestry of Homologs as well as these following databases right now. Some tools predict orthologous de novo from the input protein sequences, might not provide any Database. Among these tools are SonicParanoid and OrthoFinder.
Sources: en.wikipedia.org
Bryan Johnson (born August 22, 1977) is an American entrepreneur, venture capitalist, writer and author. He is the founder and former CEO of Kernel, a company creating devices that monitor and record brain activity, and OS Fund, a venture capital firm that invests in early-stage science and technology companies. Johnson was also the founder, chairman and CEO of Braintree, a company specializing in mobile and web payment systems for e-commerce companies. Braintree acquired Venmo in 2012 for $26.2 million; the combined entity was acquired by PayPal for $800 million in 2013. Johnson has received media attention for his anti-aging attempts, with a commercial company attached to the project called Blueprint. He refers to the philosophy as "don't die". In 2026 Johnson announced he was diagnosed with an incurable autoimmune disease.
In 2007, the Alcohol and Tobacco Tax and Trade Bureau (TTB) effectively lifted the long-standing absinthe ban, and it has since approved many brands for sale in the US market. This was made possible partly through the TTB's clarification of the Food and Drug Administration's (FDA) thujone content regulations, which specify that finished food and beverages that contain Artemisia species must be thujone-free. In this context, the TTB considers a product thujone-free if the thujone content is less than 10 ppm (equal to 10 mg/kg). This is verified through the use of gas chromatography–mass spectrometry. The brands Kübler and Lucid and their lawyers did most of the work to get absinthe legalized in the U.S., over the 2004–2007 time period. In the U.S., 5 March sometimes is referred to as "National Absinthe Day", as it was the day the 95-year ban on absinthe was finally lifted. The import, distribution, and sale of absinthe are permitted subject to the following restrictions:
Moving forward, though, the potential for real biological computers is immense. We are essentially talking about fully-functional computers that can sense their surroundings, and then manipulate their host cells into doing just about anything. Biological computers might be used as an early-warning system for disease, or simply as a diagnostic tool ... Biological computers could tell their host cells to stop producing insulin, to pump out more adrenaline, to reproduce some healthy cells to combat disease, or to stop reproducing if cancer is detected. Biological computers will probably obviate the use of many pharmaceutical drugs. UC Berkeley biochemical engineer Jay Keasling said the transcriptor "clearly demonstrates the power of synthetic biology and could revolutionize how we compute in the future".
Interleukin 34 (IL-34) is a protein belonging to a group of cytokines called interleukins. It was originally identified in humans, by large scale screening of secreted proteins; chimpanzee, murine, rat and chicken interleukin 34 orthologs have also been found. The protein is composed of 241 amino acids, 39 kilodaltons in mass, and forms homodimers. IL-34 increases growth or survival of monocytes. In cancer, IL-34 was shown to drive the migration of monocyte-derived tumor-associated macrophages in the tumor microenvironment. IL-34 elicits its activity by binding the Colony stimulating factor 1 receptor. Messenger RNA (mRNA) expression of human IL-34 is most abundant in spleen but occurs in several other tissues: thymus, liver, small intestine, colon, prostate gland, lung, heart, brain, kidney, testes, and ovary. The discovery of IL-34 protein in the red pulp of the spleen suggests involvement in growth and development of myeloid cells, consistent with its activity on monocytes.
In a typical nuclear reactor fueled with uranium-235, the presence of 135Xe as a fission product presents designers and operators with problems due to its large neutron cross section for absorption. Because absorbing neutrons can impair a nuclear reactor's ability to increase power, reactors are designed to mitigate this effect and operators are trained to anticipate and react to these transients. This practice dates to the first fission piles, constructed by the Manhattan Project during the Second World War. Enrico Fermi suspected that 135Xe would act as a powerful neutron poison and followed the advice of Emilio Segrè by contacting his student Chien-Shiung Wu. Wu's unpublished paper on 135Xe verified Fermi's guess that it absorbed neutrons and was the cause of the disruptions to the B Reactor then in use at Hanford, Washington to breed plutonium for the American implosion bomb. During periods of steady state operation at a constant neutron flux level, the 135Xe concentration builds up to its equilibrium value for that reactor power in about 40 to 50 hours. When the reactor power is increased, 135Xe concentration initially decreases because the burn up is increased at the new higher power level. Because 95% of the 135Xe production is from decay of 135I, which has a 6.58 hour half-life, the production of 135Xe remains constant; at this point, the 135Xe concentration reaches a minimum. The concentration then increases to the new equilibrium level (more accurately steady state level) for the new power level in roughly 40 to 50 hours.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.